Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-01-25
2010-06-29
Chong, Yong S (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
07745493
ABSTRACT:
The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.
REFERENCES:
patent: 4122193 (1978-10-01), Scherm et al.
patent: 4233229 (1980-11-01), Chakrabarti
patent: 4355043 (1982-10-01), Durlach
patent: 4582705 (1986-04-01), Primes et al.
patent: 5061703 (1991-10-01), Bormann et al.
patent: 5262162 (1993-11-01), Bormann et al.
patent: 5382601 (1995-01-01), Numberg et al.
patent: 5455279 (1995-10-01), Lipton
patent: 5474990 (1995-12-01), Olney
patent: 5602150 (1997-02-01), Lidsky
patent: 5614560 (1997-03-01), Lipton
patent: 5952389 (1999-09-01), Fogel
Vetulani (Review Drug Addiction. Part III. Pharmacotherapy of Addiction, Polish Journal of Pharmacology, 2001, vol. 53, pp. 415-434).
G. Bartholini.Medicinal Research Reviews. 5(1):55-75 (1985).
Berton et al.Alcoholism: Clinical and Experimental Research. 22(1):183-191 (1998).
Alexander, et al. “Serum Calcium and Magnesium in Schizophrenia: Relationship to Clinical Phenomena and Neuroleptic Treatment.” Brit. F. Psychiat. 133: 143-49 (1978).
Ananth, et al. “Meige's Syndrome Associated with Neuroleptic Treatment.” Am J. Psychiatry. 145: 4 (Apr. 1988).
Andrew. “Clinical Relationship of Extrapyramidal Symptoms and Tardive Dyskinesia.” Can. J. Psych. 39: 576-580 (1994).
Andreassen, et al., “Tardive Dyskinesia: Behavorial Effects of Repeated Intracerebroventricular Haloperidol Injections in Rats Do Not Confirm the Kindling Hypothesis”, Pharmacology Biochemistry and Behavior, 49:2, 309-312, 1994.
Andreassen, et al., “Inhibition by Memantine of the Development of Persistant Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Rats”, British Journal of Pharmacology 119: 751-757, 1996.
Arthurs, et al.; “Treatment of Blepharospasm with Medication, Surgery and Type A Botulinum Toxin”, Can J. Ophthalmol, 22:1, 1987.
Athanassenas, et al., “Serum Calcium and Magnesium Levels in Chronic Schizophrenics”, Journal of Clinical Psychopharmacology, 3:4, Aug. 1983.
Bezchilbynk-Butler et al., “Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyramidal Symptoms”, Can. J. Psych., 39:74-84, 1994.
Boumans et al., “Is the Social Acceptability of Psychiatric Patients Decreased by Orofacial Dyskinesia?”, Schizo Bull, 20:339-344, 1994.
Britton, et al., “Dextromethorphan Protects Against Cerebral Injury Following Transient, But Not Permanent, Focal Ischemia in Rats” Life Sciences, 60:20, 1729-1740, 1997.
Büchel et al., “Oral Tardive Dyskinesia: Validation of a Measuring Device Using Digital Image Processing”, Psychopharmacology-Berl, 117:162-165, 1995.
Casey, D. “Pharmacology of Blepharospasm-Oromandibular Dystonia Syndrome”, Neurology, 30:690-695, Jul. 1980.
Cassady, et al., “Neuroleptic Induced Movement Disorders”, Cambridge, England: Cambridge University Press, 1997, pp. 454-469.
Chabenat, et al., “Physicochemical, Pharmacological and Pharmacokinetic Study of a New GABAerigic Compound, Calcium Acetylhomotaurinate”, Methods Find Exp Clin Pharmacol, 10:311-7, May 1988.
Chakos et al., “Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia”, Arch Gen Psychiatry, 53:313-319, 1996.
Chappell, et al., “Future Therapies of Tourette Syndrome”,-Neurologic Clinics of North America, 15: May 2, 1997.
Chen, et al., “Focal Dystonia and Repetitive Motion Disorders”, Clinical Orthopaedics and Related Research, 351: 102-106.
Dabiri, et al., “Effectiveness of Vitamin E for Treatment of Long-Term Tardive Dyskinesia”, Am J. Psychiatry 151: Jun. 6, 1994.
Decker et al., “Amantadine Hydrochloride Treatment of Tardive Dyskinesia”, Oct. 7, New England J. Med, 285:860, 1971.
Delfs et al., “Expression of Glutamic Acid Decarboxylase mRNA in Striatum and Pallidum in a Animal Model of Tardive Dyskinesia”, Exp. Neurol, 133:175-188, 1995.
De Mattos, et al., “Distonias Aspectos Clinicose E Terapeuticos Bm 64 Pacientes”, Arq. Neuropsiquiatr, 54:30-36, 1996.
Decollogne, et al. “NMDA Receptor Complex Blockade by Oral Administration of Magnesium: Comparison with Mk-801.” Pharmacology Biochemistry and Behavior. 58(1): 261-268 (1997).
Dimpfel, “Effects of Memantine on Synaptic Transmission in the Hippocampus in Vitro”, Arzneimittelforschung, 45:1-5, 1995.
Durlach, et al., “Magnesium Status and Ageing: an Update”, Magnesium Research 11:25-42, 1997.
Egan M.F., et al., “Treatment of Tardive Dyskinesia” Schizophr Bull, 23(4):583-609 1997.
Elston, J. “The Management of Blepharospasm and Hemifacial Spasm”, J. Neurol 239:5-8, 1992.
Erna, et al., “Alcohol-Induced Vascular Damage of Brain is Ameliorated by Administration of Magnesium”, Alcohol, 15:95-103, 1998.
Erdo et al., “Memantine is Highly Potent in Protecting Cortical Cultures against Excitotoxic Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate”, Eur. J. Pharmacol, 198:215-217, 1991.
Esper, et al., “Adult-Onset Focal Dystonias: Presentation and Treatment Options”, Tennessee Medicine, Jan. 18-20, 1997.
Fariello, R.G. et al., “Homotaurine (3 Aminopropanesulfonic Acid; 3APS) Protects Froom the Convulsant and Cytotoxic Effect of Systemically Administered Kainic Acid.” Neurology, 32:241-5, Mar. 1982.
Galardi, et al., “Basal Ganglia and Thalamo-Cortical Hypermetabolism in Patients with Spasmodic Torticollis”, Acta Neurol Scand 94:172-176, 1996.
Greensmith, et al., Magnesium Ions Reduce Motoneuron Death Following Nerve Injury or Exposure toN-Methyl-D-Aspartate in the Developing Rat.
Gao et al., “Tiagabine Inhibits Haloperidol-Induced Oral Dyskinesias in Rats”, J. Neural Transmission, 95:63-69, 1994.
Gardos, et al., “The Treatment of Tardive Dyskinesias”, Psychopharmacology, 1503-1511, 1995.
Gullestad, et al., “Magnesium Status in Healthy Free-Living Elderly Norwegians”, Journal of the American College of Nutrition, 13:1,45-50.
Hallett, M. “The Neurophysiology of Dystonia”, Arch Neurol, 55: May 1998.
Hayashi et al., “Prevalence of and Risk Factors for Respiratory Dyskinesia”, Clin. Neuropharmacol, 19:390-398, 1996.
Holds, et al., “Facial Dystonia, Essential Blepharospasm and Hemifacial Spasm”, AFP, 43(6): 2113-2120, Jun. 1991.
Imamura et al., “Improved Preseveration with Amantadine”, Abstract, No-To-Shinkei, 46:556-562, 1994.
Jacoby, et al., “Diltiazem Reduces the Contractility of Extraocular Muscles in Vitro and in Vivo”, Investigative Ophthalmology & Visual Science, 31:569-576, Mar. 1990.
Jankovic, J. “Treatment of Hyperkinetic Movement Disorders with Tetrabenazine: A Double-Blind Crossover Study”, Ann Neurol 11:41-47, 1982.
Jankovic, J. “Blepharospasm and Orofacial—Cervical Dystonia: Clinical and Pharmacological Findings in 100 Patients”, Ann Neurol 13:402-411, 1983.
Jeste et al., “Risk of Tardive Dyskinesia in Older Patients. A Prospective Longitudinal Study of 266 Outpatients”, Arch Gen Psychiatry,
Chong Yong S
Knobbe Martens Olson & Bear LLP
Synchroneuron, LLC
LandOfFree
Methods of treating tardive dyskinesia and other movement... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating tardive dyskinesia and other movement..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating tardive dyskinesia and other movement... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4250603